- Home
- RERE vs CDNA Comparison
RERE vs CDNA Comparison
Compare RERE & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | CDNA |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.6M | 1.1B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RERE | CDNA |
|---|---|---|
| Price | $4.32 | $20.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 633.0K | ★ 733.8K |
| Earning Date | 05-19-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $25.70 | $16.01 |
| Revenue Next Year | $22.93 | $11.31 |
| P/E Ratio | ★ $34.57 | $409.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $2.41 | $10.96 |
| 52 Week High | $6.47 | $23.24 |
Technical Indicators
Market Signals| Indicator | RERE | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 47.72 |
| Support Level | $4.26 | $16.63 |
| Resistance Level | $4.37 | $21.20 |
| Average True Range (ATR) | 0.17 | 1.33 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 6.67 | 38.34 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.